The global alopecia drugs market was valued at US$ 6,901.8 Mn in 2016 and is projected to reach US$ 10,992.9 Mn in 2026 at a CAGR of 4.8% from 2017 to 2026. The topical segment in the global alopecia drugs market accounted for a major revenue share of 69.8% owing to factors such as easy absorption of medications by hair follicles, along with easier administration and application as compared to other forms.
Global Alopecia Drugs Market: Segmental Snapshot
By route of administration: The topical segment is estimated to register a CAGR of over 5.1%, thereby accounting for highest revenue share among the route of administration segments.
By gender: The men segment is estimated to account for highest revenue share among the gender segments, registering a CAGR of over 5.0% during the forecast period.
By region: The market in Asia Pacific is expected to record highest CAGR of over 7.3% between 2017 and 2026.
Global Alopecia Drugs Market: Competitive Analysis
The research report on the global alopecia drugs market includes detailed competitive analysis on major companies such as Taisho Pharmaceutical Holdings Co. Ltd., The Himalaya Drug Company, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., MERCK, Vitabiotic Ltd., and Sun Pharmaceutical Industries Ltd.